Airway disease: Similarities and differences between asthma, COPD and bronchiectasis

Clinics

Volumn 67, Issue 11, 2012, Pages 1335-1343

  Athanazio, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Asthma; Bronchiectasis; Chronic obstructive pulmonary disease

Indexed keywords

ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ASTHMA; BRONCHIECTASIS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84870473495     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(11)19     Document Type: Review

References (116)

1. Diretrizes da Sociedade Brasileira de Pneumologia e Tisiologia para o Manejo da Asma - 2012. J Bras Pneumol. 2012;38(1):1-58.
2. II Consenso Brasileiro sobre Doença Pulmonar Obstrutiva Crônica - DPOC. J Bras Pneumol. 2004;30(5):1-52.
3. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160:1683-1689, http://dx.doi.org/10.1001/archinte.160.11.1683.
4. Menezes AM, Jardim JR, Pérez-Padilla R, Camelier A, Rosa F, Nascimento O, et al. Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in São Paulo, Brazil. Cad Saude Publica. 2005;21(5):1565-1573, http://dx.doi.org/10.1590/S0102-311X2005000500030.
5. National Heart, Lung, and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention National Heart, Lung, and Blood Institute; updated 2010.
6. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis. 2004;8(6):691-702.
7. Celli BR, Halbert RJ, Isonaka S, Schaul B. Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22(2):268-273, http://dx.doi.org/10.1183/09031936.03.00075102.
8. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124(2):474-481, http://dx.doi.org/10.1378/chest.124.2.474.
9. Abramson M, Matheson M, Wharton C, Sim M, Walters EH. Prevalence of respiratory symptoms related to chronic obstructive pulmonary disease and asthma among middle aged and older adults. Respirology. 2002;7(4):325-331, http://dx.doi.org/10.1046/j.1440-1843.2002.00408.x.
10. Cerveri I, Accordini S, Corsico A, Zoia MC, Carrozzi L, Cazzoletti L, et al. Chronic cough and phlegm in young adults. Eur Respir J. 2003;22(3):413-417, http://dx.doi.org/10.1183/09031936.03.00121103.
11. Meyer PA, Mannino DM, Redd SC, Olson DR. Characteristics of adults dying with COPD. Chest. 2002;122(6):2003-2008, http://dx.doi.org/10.1378/chest.122.6.2003.
12. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prütz C. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002;96(9):700-708, http://dx.doi.org/10.1053/rmed.2002.1334.
13. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest. 2004;125(4):1394-1399, http://dx.doi.org/10.1378/chest.125.4.1394.
14. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ. 2003;327(7416):653-654, http://dx.doi.org/10.1136/bmj.327.7416.653.
15. Barker AF. Bronchiectasis. N Engl J Med. 2002;346(18):1383-1393.
16. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320(5):271-277.
17. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med. 1991;325(15):1067-1071.
18. Court CS, Cook DG, Strachan DP. Comparative epidemiology of atopic and non-atopic wheeze and diagnosed asthma in a national sample of English adults. Thorax. 2002;57(11):951-957, http://dx.doi.org/10.1136/thorax.57.11.951.
19. Association Asthme & Allergies. Occupational asthma dicitionnaire des allerge'nes. Palmare's 2002 des Hôpitaux. Available from http://www.asmanet.com.
20. Bezerra GF, Soares MD, Costa MR, Viana GM, Sousa MD. Environmental assessment of an asthma education program: Relationship between airborne fungi and IgE levels in children and adults. J Bras Pneumol. 2011;37(2):281-282.
21. Peden DB. Influences on the development of allergy and asthma. Toxicology. 2002;181-182:323-328, http://dx.doi.org/10.1016/S0300-483X(02)00301-3.
22. Oxman AD, Muir DC, Shannon HS, Stock SR, Hnizdo E, Lange HJ. Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am Rev Respir Dis. 1993;148(1):38-48.
23. Davison AG, Fayers PM, Taylor AJ, Venables KM, Darbyshire J, Pickering CA, et al. Cadmium fume inhalation and emphysema. 1(8587):663-667.
24. Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for obstructive airways disease among women. Chest. 1996;109(1):115-119, http://dx.doi.org/10.1378/chest.109.1.115.
25. Desalu OO, Adekoya AO, Ampitan BA. Increased risk of respiratory symptoms and chronic bronchitis in women using biomass fuels in Nigeria. J Bras Pneumol. 2010;36(4):441-446.
26. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 1995;152(5Pt2):S77-S121.
27. Chatkin G, Chatkin JM, Aued G, Petersen GO, Jeremias ET, Thiesen FV. Evaluation of the exhaled carbon monoxide levels in smokers with COPD. J Bras Pneumol. 2010;36(3):332-338.
28. Rondon EN, Silva RM, Botelho C. Respiratory symptoms as health status indicators in workers at ceramics manufacturing facilities. J Bras Pneumol. 2011;37(1):36-45.
29. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119:1691-1695, http://dx.doi.org/10.1378/chest.119.6.1691.
30. Lombardi EM, Prado GF, Santos UP, Fernandes FL. Women and smoking: Risks, impacts, and challenges. J Bras Pneumol. 2011; 37(1):118-128.
31. Castro MR, Matsuo T, Nunes SO. Clinical characteristics and quality of life of smokers at a referral center for smoking cessation. J Bras Pneumol. 2010;36(1):67-74.
32. Malta DC, Moura EC, Silva SA, Oliveira PP, Silva VL. Prevalence of smoking among adults residing in the Federal District of Brasília and in the state capitals of Brazil, 2008. J Bras Pneumol. 2010;36(1):75-83.
33. Neto AS, Andrade TM, Napoli C, Abdon LC, Garcia MR, Bastos FI. Determinants of smoking experimentation and initiation among adolescent students in the city of Salvador, Brazil. J Bras Pneumol. 2010;36(6):674-682.
34. Viegas CA, Valentim AG, Amoras AP, Nascimento EJ. Attitudes of Brazilian pulmonologists toward nicotine dependence: a national survey. J Bras Pneumol. 2010;36(2):239-242.
35. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978;204: 345-351, http://dx.doi.org/10.1111/j.0954-6820.1978.tb08452.x.
36. Barnes PJ. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax. 1999;54(3):245-252, http://dx.doi.org/10.1136/thx.54.3.245.
37. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med. 1997;156(5):1436-1439.
38. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997;350(9078):630-633, http://dx.doi.org/10.1016/S0140-6736(96)08061-0.
39. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4 Pt1):1277-1284.
40. Sherrill DL, Lebowitz MD, Halonen M, Barbee RA, Burrows B. Longitudinal evaluation of the association between pulmonary function and total serum IgE. Am J respir Crit Care Med. 1995;152(1):98-102.
41. Yunginger JW, Reed CE, O'Connell EJ, Melton LJ III, O'Fallon WM, Silverstein MD. A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am Rev Respir Dis. 1992; 146(4):888-894.
42. Bjornson CL, Mitchell I. Gender differences in asthma in childhood and adolescence. J Gend Specif Med. 2000;3(8):57-61.
43. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Ruttenvan Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164(4):590-596.
44. Silverman EK, Weiss ST, Drazen JM, Chapman HA, Carey V, Campbell EJ. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(6):2152-2158.
45. Ferrari R, Tanni SE, Lucheta PA, Faganello MM, Amaral RA, Godoy I. Gender differences in predictors of health status in patients with COPD. J Bras Pneumol. 2010;36(1):37-43.
46. Ratier JC, Pizzichini E, Pizzichini M. Astroesophageal reflux disease and airway hyperresponsiveness: concomitance beyond the realm of chance?. J Bras Pneumol. 2011;37(5):680-688.
47. Schwartz J, Gold D, Dockery DW, Weiss ST, Speizer FE. Predictors of asthma and persistent wheeze in a national sample of children in the United States. Association with social class, perinatal events, and race. Am Rev Respir Dis. 1990;142(3):555-562, http://dx.doi.org/10.1164/ajrccm/142.3.555.
48. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ. 1991;303(6804):671-675, http://dx.doi.org/10.1136/bmj.303.6804.671.
49. Gold DR, Tager IB, Weiss ST, Tosteson TD, Speizer FE. Acute lower respiratory illness in childhood as a predictor of lung function and chronic respiratory symptoms. Am Rev Respir Dis. 1989;140(4):877-884.
50. Forster J, Tacke U, Krebs H Streckter HJ, Werchau H, Bergmann RL. Respiratory syncytial virus infection: its role in aeroallergen sensitization during the first two years of life. Pediatr Allergy Immunol. 1996;7(2):55-60, http://dx.doi.org/10.1111/j.1399-3038.1996.tb00107.x.
51. Shahar E, Folsom AR, Melnick SL, Tockman MS, Comstock GW, Gennaro V, et al. Dietary n-3 polyunsaturated fatty acids and smokingrelated chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1994;331(4):228-233.
52. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol. 2003;112(5):819-827; quiz 828, http://dx.doi.org/10.1016/S0091-6749(03)02011-6.
53. Picinin IF, Camargos PA, Marguet C. Cell profile of BAL fluid in children and adolescents with and without lung disease. J Bras Pneumol. 2010;36(3):372-391.
54. Veras TN, Pizzichini E, Steidle LJ, Rocha CC, Moritz P, Pizzichini MM. Cellular composition of induced sputum in healthy adults. J Bras Pneumol. 2011;37(3):348-353.
55. Hoshino M, Nakamura Y, Sim JJ. Expression of growth factors and remodelling of the airway wall in bronchial asthma. Thorax. 1998;53(1):21-27, http://dx.doi.org/10.1136/thx.53.1.21.
56. Ward C, Pais M, Bish R, Reid D, Feitis B, Johns D, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002;57(4):309-316, http://dx.doi.org/10.1136/thorax.57.4.309.
57. Stankiewicz W, Dabrowski MP, Chcialowski A, Plusa T. Cellular and cytokine immunoregulation in patients with chronic obstructive pulmonary disease and bronchial asthma. Mediat Inflamm. 2002; 11(5):307-312, http://dx.doi.org/10.1080/09629350210000015719.
58. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977;115(2):195-205.
59. Mitsunobu F, Ashida K, Hosaki Y, Tsugeno H, Okamoto M, Nishida N, et al. Influence of long-term cigarette smoking on immunoglobulin Emediated allergy, pulmonary function, and highresolution computed tomography lung densitometry in elderly patients with asthma. Clin Exp Allergy. 2004;34(1):59-64, http://dx.doi.org/10.1111/j.1365-2222.2004.01844.x.
60. Petays T, von Hertzen L, Metso T, Rytillä P, Jousilahti P, Helenius I, Varitiainen E, et al. Smoking and atopy as determinants of sputum eosinophilia and bronchial hyper-responsiveness in adults with normal lung function. Respir Med. 2003;97(8):947-954, http://dx.doi.org/10.1016/S0954-6111(03)00122-7.
61. Brightling CE, Monteiro W, Ward R, Birring S, Green R, Siva R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480-1485, http://dx.doi.org/10.1016/S0140-6736(00)02872-5.
62. Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653.
63. Tsang KW, Bilton D. Clinical challenges in managing bronchiectasis. Respirology. 2009;14(5):637-650, http://dx.doi.org/10.1111/j.1440-1843.2009.01569.x.
64. King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411-419, http://dx.doi.org/10.2147/COPD.S6133.
65. Morrissey BM. Pathogenesis of bronchiectasis. Clin Chest Med. 2007;28(2):289-296, http://dx.doi.org/10.1016/j.ccm.2007.02.014.
66. Tambascio J, Lisboa RM, Passarelli RC, Martinez JA, Gastaldi AC. Adhesiveness and purulence of respiratory secretions: implications for mucociliary transport in patients with bronchiectasis. J Bras Pneumol. 2010;36(5):545-553.
67. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(3):418-424, http://dx.doi.org/10.1164/rccm.200203-183OC.
68. Romagnoli M, Vachier I, Tarodo de la Fuente P, Meziane H, Chavis C, Bousquet J, et al. Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J. 2002;20(6):1370-1377, http://dx.doi.org/10.1183/09031936.02.00029202.
69. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997;155(2):542-548.
70. Magnussen H, Richter K, Taube C. Are chronic obstructive pulmonary disease (COPD) and asthma different diseases? Clin Exp Allergy. 1998;28(Suppl. 5):187-194;discussion 203-5, http://dx.doi.org/10.1046/j.1365-2222.1998.028s5187.x.
71. Ponte EV, Souza-Machado A, Souza-Machado C, Franco R, Cruz AA. Clinical characteristics and prognosis in near-fatal asthma patients in Salvador, Brazil. J Bras Pneumol. 2011;37(4):431-437.
72. Vieira AA, Santoro IL, Dracoulakis S, Caetano LB, Fernandes AL. Anxiety and depression in asthma patients: impact on asthma control. J Bras Pneumol. 2011;37(1):13-18.
73. Reck CL, Fiterman-Molinari D, Barreto SS, Fiterman J. Poor perception of dyspnea following methacholine challenge test in patients with asthma. J Bras Pneumol. 2010;36(5):539-544.
74. Rogers DF. Mucus pathophysiology in COPD. differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis. 2000;55(4):324-332.
75. Ryu JH, Scanlon PD. Obstructive lung diseases: COPD, asthma, and many imitators. Mayo Clin Proc. 2001;76:1144-1153, http://dx.doi.org/10.4065/76.11.1144.
76. Camargo LA, Pereira CA. Dyspnea in COPD: Beyond the modified Medical Research Council scale. J Bras Pneumol. 2010;36(5):571-578.
77. Araujo ZT, Holanda G. Does the BODE index correlate with quality of life in patients with COPD?. J Bras Pneumol. 2010;36(4):447-452.
78. NIH/NHLBI. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD). WHO/NHLBI Workshop Report. National Institutes for Health/National Heart, Lung and Blood Institute 2011.
79. Araújo FB, Corrêa RA, Pereira LF, Silveira DC, Mancuso EV, Rezende NA. Spirometry with bronchodilator test: effect that the use of largevolume spacers with antistatic treatment has on test response. J Bras Pneumol. 2011;37(6):752-758.
80. Rodrigues MT, Fiterman-Molinari D, Barreto SS, Fiterman J. The role of the FEF50%/0.5FVC ratio in the diagnosis of obstructivelung diseases. J Bras Pneumol. 2010;36(1):44-50.
81. Hamutcu R, Rowland JM, Horn MV, Kaminsky C, MacLaughlin EF, Starnes VA, et al. Clinical findings and lung pathology in children with cystic fibrosis. Am J Respir Crit Care Med. 2002;165(8):1172-1175.
82. Wells AU. Computed tomographic imaging of bronchiolar disorders. Curr Opin Pulm Med. 1998;4(2):85-92, http://dx.doi.org/10.1097/00063198-199803000-00005.
83. Silva CI, Marchiori E, Júnior AS, Müller NL, et al. Illustrated Brazilian consensus of terms and fundamental patternsin chest CT scans. J Bras Pneumol. 2010;36(1):99-123.
84. Walker C, Gupta S, Hartley R, Brightling CE. Computed tomography scans in severe asthma: utility and clinical implications. Curr Opin Pulm Med. 2012;18(1):42-47, http://dx.doi.org/10.1097/MCP.0b013e32834db255.
85. Castro M, Fain SB, Hoffman EA, Gierada DS, Erzurum SC, Wenzel S, et al. Lung imaging in asthmatic patients: the picture is clearer. J Allergy Clin Immunol. 2011;128(3):467-478, http://dx.doi.org/10.1016/j.jaci.2011.04.051.
86. Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers: correlation with lung function. Am J Respir Crit Care Med. 2000;162:(3 Pt 1):1102-1108.
87. Cerveri I, Dore R, Corsico A, Zoia MC, Pellegrino R, Brusasco V, et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest. 2004;125(5):1714-1718, http://dx.doi.org/10.1378/chest.125.5.1714.
88. Boschetto P, Miniati M, Miotto D, Braccioni F, De Rosa E, Bononi I, et al. Predominant emphysema phenotype in chronic obstructive pulmonary. Eur Respir J. 2003;21(3):450-454.
89. Menezes AM, Macedo SE, Noal RB, Fiterman J, Cukier A, Chatkin JM, et al. Pharmacological treatment of COPD. J Bras Pneumol. 2011;37(4):527-543.
90. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(1):1-58, http://dx.doi.org/10.1136/thx.2010.136119.
91. Athanazio RA, Rached SZ, Rohde C, Pinto RC, Fernandes FL, Stelmach R. Should the bronchiectasis treatment given to cystic fibrosis patients be extrapolated to those with bronchiectasis from other causes?. J Bras Pneumol. 2010;36(4):425-431.
92. Lazarus SC, Boushey HA, Fahy JV, Chinchili VM, Lemanske RF Jr, Sorkness CA, et al. Long-acting b2-agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285(20):2583-2593, http://dx.doi.org/10.1001/jama.285.20.2583.
93. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(10 Pt 2):S28-S38.
94. Appleton S, Poole P, Smith B, Veale A, Bara A. Long-acting b2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation (Cochrane Review). Cochrane Database Syst Rev. 2002;(3):CD001104.
95. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J. 2002;19(1):182-191, http://dx.doi.org/10.1183/09031936.02.00283202.
96. Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141(2):461-468, http://dx.doi.org/10.1378/chest.11-0180.
97. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: a three-center study. Am Rev Respir Dis. 1989;139(5):1188-1191.
98. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117(2 Suppl):63S-66S, http://dx.doi.org/10.1378/chest.117.2_suppl.63S.
99. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease: a meta analysis:. Thorax 2006;61(10):854-862, http://dx.doi.org/10.1136/thx.2006.063271.
100. Fernandes FL, Pavezi VA, Dias SA, Pinto RM, Stelmach R, Cukier A. Short-term effect of tiotropium in COPD patients being treated with a β2 agonist. J Bras Pneumol. 2010;36(2):181-189.
101. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. N Engl J Med. 2012;367(13):1198-1207.
102. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998;157(3 Pt 2):S1-S53.
103. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;145(3):669-674.
104. Pereira CA, Vianna FF, Cukier A, Stelmach R, Oliveira JC, Carvalho EV, et al. Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients. J Bras Pneumol. 2010;36(4):410-416.
105. Santos DO, Martins MC, Sipriano SL, Pinto RM, Cukier A, Stelmach R. Pharmaceutical care for patients with persistent asthma: assessment of treatment compliance and use of inhaled medications. J Bras Pneumol. 2010;36(1):14-22.
106. Dalcin PT, Grutcki DM, Laporte PP, Lima PB, Viana VP, Konzen GL, et al. Impact of a short-term educational intervention on adherence to asthma treatment and on asthma control. J Bras Pneumol. 2011;37(1):19-27.
107. Coelho AC, Souza-Machado A, Leite M, Almeida P, Castro L, Cruz CS, et al. Use of inhaler devices and asthma control in severe asthma patients at a referral center in the city of Salvador, Brazil. J Bras Pneumol. 2011;37(6):720-728.
108. Pereira ED, Cavalcante AG, Pereira EN, Lucas P, Holanda MA. Asthma control and quality of life in patients with moderate or severe asthma. J Bras Pneumol 2011;37(6):704-711.
109. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297-1303, http://dx.doi.org/10.1136/bmj.320.7245.1297.
110. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166:1358-1363, http://dx.doi.org/10.1164/rccm.200206-512OC.
111. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev. 2009;21;(1):CD000996. Review.
112. Decramer M, Gosselink, R, Bartsch P, Lofdahl CG, Vincken W, Dekhuijzen R, et al. Effect of treatments on the progression of COPD: Report of a workshop held in Leuven, March 11-12 2004. Thorax. 2005;60(4):343-349, http://dx.doi.org/10.1136/thx.2004.028720.
113. Rubin AS, Cardoso PF. Bronchial thermoplasty in asthma. J Bras Pneumol. 2010;36(4):506-512.
114. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356(13):1327-1337.
115. Wehrmeister FC, Knorst M, Jardim JR, Macedo SE, Noal RB, Martínez-Mesa J, et al. Pulmonary rehabilitation programs for patients with COPD. J Bras Pneumol. 2011;37(4):544-555.
116. Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev. 2002;(3):CD002166. Review.